Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

Blood (2024) 144 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2024-207871

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Blood (2024) 144 (Supplement 1): 471.

https://doi.org/10.1182/blood-2024-205809

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Blood (2024) 144 (Supplement 1): 342.

https://doi.org/10.1182/blood-2024-200262

Published: 2024

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 3009.

https://doi.org/10.1182/blood-2024-205671

Published: 2024

Journal Articles

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Blood (2023) 142 (Supplement 1): 3927.

https://doi.org/10.1182/blood-2023-191146

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Blood (2023) 142 (Supplement 1): 6168.

https://doi.org/10.1182/blood-2023-186019

Published: 2023

Journal Articles

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Blood (2023) 142 (Supplement 1): 786.

https://doi.org/10.1182/blood-2023-186730

Published: 2023

Journal Articles

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Blood (2023) 142 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2023-180333

Published: 2023

Journal Articles

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

Sarka Pavlova, Jitka Malcikova, Lenka Radova, Silvia Bonfiglio, Jack B. Cowland, Christian Brieghel, Mette Klarskov Andersen, Maria Karypidou, Bella V Biderman, Michael Doubek, Gregory Lazarian, Inmaculada Rapado, Matthijs Vynck, Naomi Porret, Martin Andres, Dina Rosenberg, Dvora Sahar, Carolina Martinez-Laperche, Ismael Buño Borde, Andrew Hindley, Julio Bravo Sánchez, José García-Marco, Alicia Serrano, Blanca Ferrer Lores, Concepción Fernández-Rodriguez, Beatriz Bellosillo, Stephan Stilgenbauer, Eugen Tausch, Hero Nikdin, Fiona Quinn, Emer Atkinson, Lisette Van De Corput, Cafer Yildiz, Cristina Bilbao, Yanira Florido, Christian Thiede, Caroline Schuster, Anastazja Stoj, Sylwia Czekalska, Anastasia Chatzidimitriou, Stamatia Laidou, Audrey Bidet, Charles Dussiau, Friedel Nollet, Giovanna Piras, Tereza Borosova, Terezia Kurucova, Maria Monne, Svetlana Smirnova, Evgeny Nikitin, Ivan Sloma, Marie-Helene Delfau, Laetitia Largeaud, Loic Ysebaert, Peter J. M. Valk, Amy Christian, Renata Walewska, Marta Sebastião, Maria Gomes da Silva, Piero Galieni, Mario Angelini, Davide Rossi, Valeria Spina, Sónia Matos, Vânia Martins, David Donaldson, Tomasz Stoklosa, Monika Pepek, Panagiotis Baliakas, Rafa Andreu, Irene Luna, Tiina Kahre, Ülle Murumets, Sophie Laird, Daniel Ward, Miguel Alcoceba, Ana Balanzategui, Lydia Scarfo, Francesca Gandini, Ettore Zapparoli, Adoracion Blanco, Pau Abrisqueta Costa, Ana E. Rodriguez, Maria Rocio Benito Sanchez, Frédéric Davi, Clothilde Bravetti, Paula Gameiro, Joaquin Martinez-Lopez, Barbara Tazon, Fanny Baran-Marszak, Zadie Davies, Mark Caterwood, Andrey B Sudarikov, Richard Rosenquist, Carsten Utoft Niemann, Kostas Stamatopoulos, Paolo Ghia, Sarka Pospisilova

Blood (2023) 142 (Supplement 1): 200.

https://doi.org/10.1182/blood-2023-173235

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Blood (2023) 142 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2023-186072

Published: 2023

Journal Articles

Key Prognostic Factors in Patients with Relapsed/Refractory Follicular Lymphoma: An Evidence Based Systematic Literature and Medical Review

Ana Jimenez Ubieto, Pau Abrisqueta Costa, Christian Hampp, Shivani Aggarwal, Mohsin Shah, Laura Walsh, Eileen Thorley, Qiufei Ma, Bastian von Tresckow

Blood (2023) 142 (Supplement 1): 7261.

https://doi.org/10.1182/blood-2023-186303

Published: 2023

Journal Articles

Key Prognostic Factors in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Evidence Based Systematic Literature and Medical Review

Bastian von Tresckow, Pau Abrisqueta Costa, Shivani Aggarwal, Christian Hampp, Laura Walsh, Eileen Thorley, Mohsin Shah, Qiufei Ma, Ana Jimenez Ubieto

Blood (2023) 142 (Supplement 1): 7258.

https://doi.org/10.1182/blood-2023-179927

Published: 2023

Journal Articles

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Johannes Duell, Wojciech Jurczak, Anna Marina Liberati, Janusz Halka, Esther Pena Carbó, Pau Abrisqueta Costa, Kami J. Maddocks, Martin Dreyling, Andreas Rosenwald, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

Blood (2022) 140 (Supplement 1): 6596–6598.

https://doi.org/10.1182/blood-2022-159983

Published: 2022

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

NARROW

Immunotherapy May be Preferable to Chemotherapy As Second-Line Treatment for POD24 Follicular Lymphoma (FL) Patients

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Incidence, Risk Factors and Clinical Impact of Sars-Cov-2 Prolonged Viral Shedding in Patients Diagnosed with Hematologic Malignancies

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Laboratories Can Reliably Detect Clinically Relevant Variants in the TP53 Gene below 10 % Allelic Frequency: A Multicenter Study of ERIC, the European Research Initiative on CLL

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Key Prognostic Factors in Patients with Relapsed/Refractory Follicular Lymphoma: An Evidence Based Systematic Literature and Medical Review

Key Prognostic Factors in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Evidence Based Systematic Literature and Medical Review

L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only